Early Safety and Clinical Efficacy of Mitral Allograft in Tricuspid Surgery

Early Safety and Clinical Efficacy of Mitral Allografts in Patients With Primary Tricuspid Valve Disease Scheduled for Tricuspid Valve Replacement

The aim of the study is to evaluate early safety and clinical efficacy of mitral allografts in tricuspid valve replacement for primary tricuspid valve diseases.

Early safety (morbidity, mortality rate, freedom from any valve related complication) along with mid-term clinical efficacy ( mid-term survival, freedom from reoperation, repeat endocarditis and other valve related complication ) is going to be evaluated.

Inclusion Criteria:

• Patients with primary tricuspid valve disease and/or tricuspid bioprosthetic failure scheduled for tricuspid valve intervention.
• Intraoperative findings suggested for tricuspid valve replacement rather than repair.

Exclusion Criteria:

• Pregnancy
• Confirmed active drug addiction
• Progressive HIV-infection
• HIV-infected patients with CD4-cells count less than 250
• Patients with secondary tricuspid valve pathology (left-sided valve disease)
• LV Ejection fraction less than 50%